PBE

Under normal circumstances, at least 80% of the value of its net assets, plus the amount of any borrowings for investment purposes, in securities of companies engaged in biotechnology- and genome-related industries, and in derivatives and other investments that have economic characteristics similar to securities of companies engaged in biotechnology- and genome-related industries (the “80% investment policy”). It is non-diversified.